Jubilant Pharmova Shares See Massive Block Trade Worth Rs. 512 Crore on NSE 4 days ago
A large block trade of approximately 4,804,883 shares of Jubilant Pharmova Ltd. occurred on the National Stock Exchange (NSE). The transaction, valued at Rs. 511.96 crore, was executed at Rs. 1,065.50 per share. This significant trade indicates potential changes in the company's ownership structure and provides a reference point for market valuation. Jubilant Pharmova, a key player in the Indian pharmaceutical sector, operates in contract research and development services, proprietary novel drugs, and radiopharmaceuticals.
Jubilant Pharmova to Transfer API Business to Wholly Owned Subsidiary 5 days ago
Jubilant Pharmova to Transfer API Division to Wholly Owned Subsidiary 5 days ago
Jubilant Pharmova Expands Global R&D Footprint with Strategic Acquisition in France Mar 20, 2025
Jubilant Pharmova's US Subsidiary Clears USFDA Inspection with VAI Status Mar 13, 2025
More news about Jubilant Pharmova
12Mar 25
Jubilant Pharmova's US Subsidiary Clears FDA Inspection with VAI Status
Jubilant Cadista Pharmaceuticals Inc., a US subsidiary of Jubilant Pharmova, received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the FDA for its Salisbury, Maryland facility in January 2025. The inspection concluded satisfactorily, allowing continued operations without major regulatory concerns. However, the company has previously announced the closure of manufacturing operations at this facility, as disclosed in April 2024.